Filtered By:
Infectious Disease: Hepatitis
Drug: Hydrocortisone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 5 results found since Jan 2013.
A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
Intern Med. 2022 Apr 30. doi: 10.2169/internalmedicine.9393-22. Online ahead of print.ABSTRACTA 63-year-old man with hepatitis C was treated with atezolizumab plus bevacizumab for unresectable diffuse hepatocellular carcinoma (HCC). After four cycles of atezolizumab plus bevacizumab, the diffuse HCC markedly shrank; however, he complained of general fatigue, loss of appetite, and slight loss of muscle strength in the lower legs. He was diagnosed with isolated adrenocorticotropic hormone deficiency (IAD), hypothyroidism, and myopathy, suggesting multisystem immune-related adverse events (irAEs). After administration of hydr...
Source: Internal Medicine - May 1, 2022 Category: Internal Medicine Authors: Hidemi Hayashi Koji Sawada Takumu Hasebe Shunsuke Nakajima Jun Sawada Yuri Takiyama Yumi Takiyama Toshikatsu Okumura Mikihiro Fujiya Source Type: research
